TuHURA Biosciences included in Russell 3000 and 2000 Indexes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2025
0mins
TuHURA Biosciences Index Inclusion: TuHURA Biosciences has been added to the Russell 3000 Index and automatically included in the Russell 2000 Index as part of the 2025 annual reconstitution, effective June 27th.
Impact of Russell Indexes: The Russell U.S. Indexes, which include over $10 trillion in assets, are managed by FTSE Russell, a subsidiary of the London Stock Exchange Group.
Analyst Views on HURA
Wall Street analysts forecast HURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HURA is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.679
Low
8.00
Averages
9.00
High
10.00
Current: 0.679
Low
8.00
Averages
9.00
High
10.00
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








